Results 151 to 160 of about 19,986 (197)
Some of the next articles are maybe not open access.
Hypolipidemic Drugs and Lipoprotein Metabolism
1972Insight into the mechanism of action and efficacy of hypolipidemic drugs has awaited the development of the current concepts of lipid transport (1). Fundamental is the fact that the blood fats-- cholesterol, phospholipid, and triglyceride-- do not circulate free in the plasma.
R I, Levy, T, Langer
openaire +2 more sources
Mechanism of Action of Hypolipidemic Drugs
1975Drugs may decrease serum lipid levels by impairing lipid absorption, lipoprotein synthesis or release, or by stimulating lipid or lipoprotein catabolism (45). Recent data point out, however, that agents such as Clofibrate (CPIB), generally thought to act only by inhibiting lipid and lipoprotein synthesis and release (3), may also affect lipid ...
C R, Sirtori +2 more
openaire +2 more sources
Synthesis of Potential Hypolipidemic Agents
Journal of Pharmaceutical Sciences, 1969Derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid (I) and 2-(p-chlorophenylthio)-2-methylpropionic acid (II) have been synthesized for the purpose of studying their potential hypolipidemic activity.
openaire +2 more sources
Presse medicale (Paris, France : 1983), 1987
All types of hyperlipoproteinaemia must be corrected to prevent or delay the atheroma they produce, or even bring about its regression. A dietetic regimen is prescribed first to be completed, if necessary, by a medicinal treatment. Once instituted, these treatments must be pursued indefinitely, the return to normal lipid levels being a sign of their ...
openaire +1 more source
All types of hyperlipoproteinaemia must be corrected to prevent or delay the atheroma they produce, or even bring about its regression. A dietetic regimen is prescribed first to be completed, if necessary, by a medicinal treatment. Once instituted, these treatments must be pursued indefinitely, the return to normal lipid levels being a sign of their ...
openaire +1 more source
HYPOLIPIDEMIC DRUGS AND HYPERLIPOPROTEINEMIA
Annals of the New York Academy of Sciences, 1971R I, Levy, T, Langer
openaire +2 more sources
[Aryloxy- and arylthioalkylamine hypolipidemic agents].
Il Farmaco; edizione scientifica, 1983Aryloxy and arylthioalkylamines related respectively to clofibrate and 2-(3,5-di-t-butyl-4-hydroxyphenylthio)hexanoic acid, a derivative of an active probucol metabolite, were prepared and pharmacologically screened as hypolipidemic substances. Some of them showed interesting antilipemic activity but also, unfortunately, high acute toxicity.
DURANTI E +5 more
openaire +2 more sources
Hypolipidemic effects of metformin in hyperprebetalipoproteinemia.
Diabete & metabolisme, 1976Metformin's hypolipidemic effects (2.55 g/day for 3 months) have been studied in 19 subjects with Fredrickson's Type IV hyperprebetalipoproteinemia. The majority of patients were above ideal body weight (relative body weight = 118 +/- 2.7 %). Eleven of the subjects presented chemical diabetes, 5 fasting hyperglycemia, and 3 normal glucose tolerance ...
D. Fedele +6 more
openaire +2 more sources
Hypolipidemic alkoxybenzoic acids
Journal of Medicinal Chemistry, 1976V G, DeVries +3 more
openaire +2 more sources